Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome

[1]  Jorge Oliver-De La Cruz,et al.  Role of mitochondria ROS generation in ethanol-induced NLRP3 inflammasome activation and cell death in astroglial cells , 2014, Front. Cell. Neurosci..

[2]  P. Sanberg,et al.  The innate and adaptive immunological aspects in neurodegenerative diseases , 2014, Journal of Neuroimmunology.

[3]  S. Ray,et al.  Understanding heterogeneity in the host response to Staphylococcus aureus infection for prognostic biomarker discovery , 2014, Critical Care.

[4]  Zhigang Tian,et al.  Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. , 2013, Immunity.

[5]  M. Brucale,et al.  Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies , 2013, PloS one.

[6]  Junying Yuan,et al.  Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. , 2013, Molecular cell.

[7]  W. Shao,et al.  Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin , 2012, Nature.

[8]  Hardy Kornfeld,et al.  Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1β , 2012, Nature Immunology.

[9]  R. Germain,et al.  The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP , 2012, Nature.

[10]  Vishva M Dixit,et al.  Inflammasomes and their roles in health and disease. , 2012, Annual review of cell and developmental biology.

[11]  E. Alnemri,et al.  Non-transcriptional Priming and Deubiquitination Regulate NLRP3 Inflammasome Activation* , 2012, The Journal of Biological Chemistry.

[12]  Perry Vh.  Innate Inflammation in Parkinson’s Disease , 2012 .

[13]  K. Tracey,et al.  Rethinking inflammation: neural circuits in the regulation of immunity , 2012, Immunological reviews.

[14]  A. Nishi,et al.  Mechanisms for the Modulation of Dopamine D1 Receptor Signaling in Striatal Neurons , 2011, Front. Neuroanat..

[15]  Haitao Wen,et al.  The inflammasome NLRs in immunity, inflammation, and associated diseases. , 2011, Annual review of immunology.

[16]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[17]  Jonathan L. Schmid-Burgk,et al.  Inflammasomes: current understanding and open questions , 2011, Cellular and Molecular Life Sciences.

[18]  Pedro Romero,et al.  Type I interferon inhibits interleukin-1 production and inflammasome activation. , 2011, Immunity.

[19]  S. Basu,et al.  The immunoregulatory role of dopamine: An update , 2010, Brain, Behavior, and Immunity.

[20]  J. Vincent,et al.  Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.

[21]  J. Bos,et al.  Epac: defining a new mechanism for cAMP action. , 2010, Annual review of pharmacology and toxicology.

[22]  Tony Wyss-Coray,et al.  Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little? , 2009, Neuron.

[23]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[24]  G. Núñez,et al.  Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation1 , 2009, The Journal of Immunology.

[25]  K. Tracey.  Reflex control of immunity , 2009, Nature Reviews Immunology.

[26]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[27]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[28]  M. Goldman.  Faculty Opinions recommendation of The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. , 2008 .

[29]  U. R. Chowdhury,et al.  Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. , 2008, The Journal of clinical investigation.

[30]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[31]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[32]  N. Barnes,et al.  Close encounters of the monoamine kind: immune cells betray their nervous disposition , 2005, Immunology.

[33]  B. Yard,et al.  Clinical review: Immunomodulatory effects of dopamine in general inflammation , 2004, Critical care.

[34]  T. Sotnikova,et al.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Serratosa,et al.  High‐yield isolation of murine microglia by mild trypsinization , 2003, Glia.

[36]  A. Mondal,et al.  Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. , 2003, International immunopharmacology.

[37]  R. Moots,et al.  Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study , 2002, Journal of Neuroimmunology.

[38]  F. Gonon,et al.  Changes in Extracellular Dopamine Induced by Morphine and Cocaine: Crucial Control by D2 Receptors , 2002, The Journal of Neuroscience.

[39]  Janice A. Nagy,et al.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor , 2001, Nature Medicine.

[40]  S. Basu,et al.  Dopamine, a neurotransmitter, influences the immune system , 2000, Journal of Neuroimmunology.

[41]  S. Tayebati,et al.  Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes , 1999, Journal of Neuroimmunology.

[42]  R. G. Allen,et al.  Pituitary Lactotroph Hyperplasia and Chronic Hyperprolactinemia in Dopamine D2 Receptor-Deficient Mice , 1997, Neuron.

[43]  J. Bergquist,et al.  Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis , 1996, Immunology.

[44]  C. Gerfen,et al.  Altered striatal function in a mutant mouse lacking D1A dopamine receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Bergquist,et al.  Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  V. Perry.  Innate inflammation in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[47]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[48]  Ashley Harms.  Inflammation in Parkinson's disease. , 2001, Advances in neurology.

[49]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.